PharmaCyte Biotech Inc Dossier - Source-backed chat

PharmaCyte Biotech Inc

PMCBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.79

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.40Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $4.3M

Enterprise Value −$13.4M

Shares Outstanding 12.3M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

PharmaCyte Biotech is a highly speculative, pre-revenue micro-cap biotechnology company. While its balance sheet is currently bolstered by a cash position that exceeds its market capitalization (following strategic asset sales such as the Femasys note monetization), its core operational execution remains deeply flawed. The company has been on a multi-year FDA clinical hold since October 2020 for its lead pancreatic cancer candidate, CypCaps. Furthermore, its capital allocation is highly unusual for a biotech firm, with general and administrative (G&A) overhead vastly outspending actual research and development (R&D) activities. Instead of aggressively advancing its own pipeline, the company has repeatedly cycled capital through investments in other micro-cap biotech entities, signaling a lack of operational focus and a slow path to commercialization.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The FDA clinical hold is never lifted, or further preclinical studies reveal safety/efficacy issues. The company continues to burn through its remaining cash on high administrative overhead and poor external investments, eventually forcing dilutive capital raises or liquidation, resulting in near-total loss of shareholder value.

Base CaseCentral scenario

The company remains in a prolonged pre-revenue state, struggling to lift the FDA clinical hold on its pancreatic cancer program. Cash reserves are gradually depleted by high corporate overhead (G&A) and passive investments in external biotech entities, leading to continued long-term share price stagnation or decline.

Bull CaseUpside scenario

PharmaCyte Biotech presents a compelling bull case driven by its proprietary Cell-in-a-Box® live-cell encapsulation technology, which enables targeted delivery of chemotherapy (such as low-dose ifosfamide) directly to tumor sites (e.g., pancreatic cancer and malignant ascites) to maximize efficacy while minimizing systemic toxicity. Furthermore, the company maintains a highly robust, debt-free balance sheet with approximately $20 million in cash and $25 million in marketable securities (following the successful monetization of its Femasys stake), providing substantial non-dilutive capital to fund strategic life sciences investments and potential clinical advancements.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong balance sheet with zero debt and cash reserves exceeding the current market capitalization.
Discretionary reverse stock split authority provides the board with a mechanism to maintain Nasdaq listing compliance.
Cell-in-a-Box technology offers a unique, localized delivery platform for chemotherapy if clinical hurdles can be overcome.

Key Investment Risks

Lead product candidate (CypCaps) has been on an FDA clinical hold since October 2020, severely delaying development.
Severe capital allocation imbalance, with G&A expenses historically dwarfing R&D expenditures.
Pre-revenue status with a history of substantial accumulated deficits ($100 million as of January 31, 2026).
Extremely small operational footprint (2-4 full-time employees) limits execution capability.

Thesis Invalidation Triggers

Official FDA announcement lifting the clinical hold on the LAPC IND.
Execution of a major co-development or licensing partnership with an established biopharmaceutical company.
A drastic restructuring of corporate expenses to prioritize R&D over G&A overhead.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.